AstraZeneca’s Anselamimab Shows Promise in Subgroup of Amyloidosis Patients

AstraZeneca ( (GB:AZN) ) has issued an announcement.

AstraZeneca’s CARES Phase III clinical program for anselamimab in light chain amyloidosis did not achieve statistical significance for the primary endpoint in the overall patient population. However, anselamimab showed clinically meaningful improvements in survival and cardiovascular hospitalization in a prespecified subgroup of patients, indicating potential to address a critical treatment gap. The investigational drug was well tolerated, and further evaluation is ongoing to assess its efficacy and safety, with plans to share data with global health authorities.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s strong financial performance and positive corporate events significantly contribute to its high overall stock score. While the technical analysis shows mixed signals, the company’s strategic advancements and robust earnings outlook support a favorable investment case.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company is based in Cambridge, UK, and its medicines are sold in over 125 countries. AstraZeneca’s subsidiary, Alexion, specializes in rare diseases, aiming to deliver life-changing medicines through innovative modalities.

Average Trading Volume: 2,242,834

Technical Sentiment Signal: Hold

Current Market Cap: £165.3B

For an in-depth examination of AZN stock, go to TipRanks’ Overview page.